Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

NCT01709942

PCOS OHSS INFERTILITY

COMPLETED PHASE3

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

NCT01360996

Polycystic Ovary Syndrome

COMPLETED PHASE4

Oral Contraceptive and Cardiovascular Risk in PCOS

NCT00593294

Polycystic Ovary Syndrome

COMPLETED PHASE4

A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS

NCT06545994

Polycystic Ovary Syndrome Pregnancy Complications

RECRUITING

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849

Reproductive Disorder PCOS Polycystic Ovary Syndrome

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There will be 2 groups of treatment; each group will consist of 62 subjects with the treatment regimens :

* Treatment I : 1 capsule of DLBS3233 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
* Treatment II : 1 caplet of Metformin XR 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily) for 6 months of treatment.

Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every interval of 1 month.

Laboratory examinations to evaluate the metabolic efficacy parameters and ultrasonography (USG) examination will be performed at baseline, Month 3rd, and end of study (Month 6th). In addition to that, USG will also be performed about 2 weeks after Month 3rd (Month 3.5th) and after Month 5th (Month 5.5th).

Laboratory examinations to evaluate the reproductive efficacy parameters (reproductive hormone levels) and safety, at baseline and Month 6th (end of study).

General counseling on lifestyle modification will be provided to the subjects by the assigned Nutritionist. All study subjects should follow a lifestyle modification. Evaluation on subjects' performance on lifestyle modification will be conducted every follow-up visit by Investigator, but particularly at baseline, Month 3rd, and end of study (Month 6th) by the Nutritionist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome (PCOS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment I

1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)

Group Type EXPERIMENTAL

DLBS3233

Intervention Type DRUG

1 DLBS3233 capsule 100 mg once daily for 6 months

Placebo caplet of Metformin XR

Intervention Type DRUG

1 placebo caplet of Metformin XR twice daily for 6 months

Treatment II

1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)

Group Type ACTIVE_COMPARATOR

Metformin XR

Intervention Type DRUG

1 Metformin XR caplet 750 mg twice daily for 6 months

Placebo capsule of DLBS3233

Intervention Type DRUG

1 placebo capsule of DLBS3233 once daily for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DLBS3233

1 DLBS3233 capsule 100 mg once daily for 6 months

Intervention Type DRUG

Metformin XR

1 Metformin XR caplet 750 mg twice daily for 6 months

Intervention Type DRUG

Placebo caplet of Metformin XR

1 placebo caplet of Metformin XR twice daily for 6 months

Intervention Type DRUG

Placebo capsule of DLBS3233

1 placebo capsule of DLBS3233 once daily for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inlacin Glumin XR Placebo caplet of Glumin XR Placebo capsule of Inlacin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female subjects in reproductive age (i.e. 18-40 years)
* Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the Rotterdam Criteria
* Subject with insulin resistance defined by: HOMA-IR of \> 2.00

Exclusion Criteria

* Pregnant and lactating women
* Subjects known to have Cushing's syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumors, uncontrolled thyroid disease, hyperprolactinemia
* Known to have current medical condition, which, is judged by the Investigator could jeopardize subject's health or interfere with the study evaluation, such as diabetes mellitus, uncontrolled hypertension, other cardiovascular diseases, acute or chronic infections, and any known malignancies
* Impaired renal function (serum creatinine level \> 1.5 ULN)
* Impaired liver function (serum ALT level ≥ 2.5 ULN)
* Medically-assisted weight loss with medications or surgical procedures
* Currently having laparoscopic ovarian diathermy (LOD)
* Currently under treatment with in vitro fertilization (IVF) techniques
* Have been regularly taking any medications which affect insulin sensitivity as well as reproductive function (i.e. ovulation, menstrual cycle), within ≤ 3 months prior to screening
* Participating in other clinical trial within 30 days prior to screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andon Hestiantoro, dr., SpOG(K)

Role: PRINCIPAL_INVESTIGATOR

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia